{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:56:40Z","timestamp":1768402600137,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"India Ministry of Science & Technology Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry\/30\/2018"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/30\/2018"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bbamcr.2025.120096","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T07:59:50Z","timestamp":1765353590000},"page":"120096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained Galiellalactone treatment breaks the metastatic resilience of BRAF-inhibitor-resistant melanoma cells"],"prefix":"10.1016","volume":"1873","author":[{"given":"Sujoy","family":"Bhowmik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya Ranjan","family":"Badajena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyajit Laxman","family":"Murkute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dumarapu","family":"Bhagyalaxmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purusottam","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbamcr.2025.120096_bb0005","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","article-title":"Activation of Stat3 in human melanoma promotes brain metastasis","volume":"66","author":"Xie","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbamcr.2025.120096_bb0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/1878-0261.12433","article-title":"Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells","volume":"13","author":"Mohapatra","year":"2019","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.bbamcr.2025.120096_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2020.111942","article-title":"Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells","volume":"390","author":"Zhao","year":"2020","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2025.120096_bb0020","article-title":"CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.bbamcr.2025.120096_bb0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbamcr.2025.120096_bb0030","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1074\/jbc.M114.564252","article-title":"Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells","volume":"289","author":"Don-Doncow","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"April","key":"10.1016\/j.bbamcr.2025.120096_bb0035","article-title":"To inhibit TrxR1 is to inactivate STAT3\u2013inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors","volume":"36","author":"Busker","year":"2020","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.bbamcr.2025.120096_bb0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.eururo.2015.06.016","article-title":"The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer","volume":"69","author":"Canesin","year":"2016","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.bbamcr.2025.120096_bb0045","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1021\/acs.jmedchem.5b01814","article-title":"Preclinical characterization of 3\u03b2-(N-acetyl l-cysteine methyl ester)-2a\u03b2, 3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer","volume":"59","author":"Escobar","year":"2016","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bbamcr.2025.120096_bb0050","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1158\/1535-7163.MCT-18-0508","article-title":"The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models","volume":"17","author":"Handle","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbamcr.2025.120096_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/pros.20699","article-title":"Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3","volume":"68","author":"Hellsten","year":"2008","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.bbamcr.2025.120096_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022118","article-title":"Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells","volume":"6","author":"Hellsten","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbamcr.2025.120096_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-35612-z","article-title":"Galiellalactone inhibits the STAT3\/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer","volume":"8","author":"Thaper","year":"2018","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.bbamcr.2025.120096_bb0070","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1016\/j.bmc.2017.06.036","article-title":"Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines","volume":"25","author":"Kim","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bbamcr.2025.120096_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom9050170","article-title":"Novel galiellalactone analogues can target stat3 phosphorylation and cause apoptosis in triple-negative breast cancer","volume":"9","author":"Ko","year":"2019","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.bbamcr.2025.120096_bb0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jcp-2022-208615","article-title":"Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy","volume":"77","author":"Martinovi\u0107","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bbamcr.2025.120096_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2022.06.001","article-title":"Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma","volume":"26","author":"Kim","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.bbamcr.2025.120096_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2025.120096_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-016-0309-7","article-title":"Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn\u2019s disease: a case report","volume":"9","author":"Uemura","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bbamcr.2025.120096_bb0100","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/2326-6066.CIR-14-0167","article-title":"Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy","volume":"3","author":"Holtzhausen","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbamcr.2025.120096_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15279","article-title":"The signalling receptor MCAM coordinates apical-basal polarity and planar cell polarity during morphogenesis","volume":"8","author":"Gao","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120096_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3803","article-title":"Wnt5a uses CD146 as a receptor to regulate cell motility and convergent extension","volume":"4","author":"Ye","year":"2013","journal-title":"Nat. Commun."},{"issue":"7547","key":"10.1016\/j.bbamcr.2025.120096_bb0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumor secretomes promote resistance and tumor progression","volume":"520","author":"Obenauf","year":"2015","journal-title":"Nature"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488925002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488925002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:16:31Z","timestamp":1768382191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488925002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0167488925002010"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2025.120096","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained Galiellalactone treatment breaks the metastatic resilience of BRAF-inhibitor-resistant melanoma cells","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2025.120096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120096"}}